Cost-Effectiveness of Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia in the United Kingdom
Abstract
Authors
C. Leteneux L. Claxton W.A. Malcolm M. Taylor H. Rathi